Gimeracil

Research use only, not for human use.

An inhibitor of dihydropyrimidine dehydrogenase, degrades pyrimidine including 5-fluorouracil in the blood.

An inhibitor of dihydropyrimidine dehydrogenase, degrades pyrimidine including 5-fluorouracil in the blood; inhibits homologous recombination. Chemotherapeutic Agents Approved(In Vitro):Gimeracil reduces the frequency of neo-positive clones. Additionally, it sensitized the cells in S-phase more than in G0/G1.Gimeracil may enhance the efficacy of radiotherapy through the suppression of HR-mediated DNA repair pathways.Gimeracil pretreatment significantly restrains the formation of radiation-induced foci of Rad51 and RPA, whereas it increased the number of foci of Nbs1, Mre11, Rad50, and FancD2. (In Vivo):Gimeracil (2.5-25 mg/kg, orally) may inhibit the rapid repair of X-ray-induced DNA damage in tumors.

——

Animal Model:Nude mice (Lu-99, LC-11, KB/C3 and PAN-4 tumors were xenografted).Dosage:2.5-25 mg/kg.Administration:Orally.Result:Exhibited anti-tumor activity.

Gimestat

Others

Other Targets

DHPS

Cancer

Chemotherapeutic

103766-25-2

145.5438

C5H4ClNO2

>98% (HPLC)

DMSO: 29 mg/mL

O=C1C=C(O)NC=C1Cl

2(1H)-Pyridinone, 5-chloro-4-hydroxy-

(-20℃)

With Ice Pack

≥ 2 years